Drug-induced aplastic anaemia and agranulocytosis. Incidence and mechanisms.
Aplastic anaemia and agranulocytosis are uncommon but serious adverse effects of drug therapy. They result from an adverse interaction between the drug and the haemopoietic pathway in certain susceptible individuals. The nature of this idiosyncratic interaction differs for different drugs and possibly for different individuals. In some instances an immune mechanism might be implicated, in others the patient's cells might carry a genetic susceptibility to the drug, while yet other patients might metabolise the drug abnormally. The idiosyncratic nature of these effects has made their investigation difficult, but experimental studies have allowed some progress in our understanding. In a practical sense, however, responsibility for preventing these problems will remain with clinicians, who should be alert to the risks and revise their prescribing habits accordingly.
D000380:Agranulocytosis / Q000139:chemically induced*; D000632:Aminopyrine / Q000009:adverse effects; D000741:Anemia, Aplastic / Q000139:chemically induced*; D000818:Animals; D001853:Bone Marrow / Q000187:drug effects; D002701:Chloramphenicol / Q000009:adverse effects; D002746:Chlorpromazine / Q000009:adverse effects; D004920:Erythropoiesis / Q000187:drug effects; D006098:Granulocytes / Q000187:drug effects; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D051379:Mice; D013234:Stem Cells / Q000187:drug effects
D000632:Aminopyrine; D002701:Chloramphenicol; D002746:Chlorpromazine